Awardee OrganizationOREGON HEALTH & SCIENCE UNIVERSITY
Description
Abstract Text
Elevated intracellular calcium is one of the most important signaling
molecules in cells, especially in neural tissues. One of the important
actions of calcium is to regulate the transcription of selected genes,
thereby altering the phenotype of the cell. Studies from a number of
laboratories, including our own, have demonstrated that a family of
calmodulin-dependent protein kinases mediate many of these Ca2+-
dependent transcriptional events. In particular, we have focused on
CaM-kinase IV which can phosphorylate several transactivating
proteins such as CREB and SRF. In the past two years we have
partially characterized a CaM-kinase cascade consisting of a CaM-
kinase kinase which can phosphorylate and activate CaM-kinase IV and
CaM-kinase I. In the current grant application we will further
characterize the involvement of this CaM-kinase cascade by: 1)
identifying additional upstream components of the cascade (e.g. CaM-
kinase kinase kinase) or anchoring proteins for CaM-kinase kinase. 2)
identifying additional transactivating proteins for CaM-kinase IV by
examining transcriptional regulation of the NGFI-B gene by the CaM-
kinase cascade. 3) determining the sites and physiological relevance
of cross-talk between the CaM-kinase cascade and the MAP-kinase
cascade.
These studies will be performed in a variety of cultured cells,
especially PC12 cells, and will utilize biochemical and molecular
biological techniques. The results of this study have implications for
modulating cellular apoptosis and synaptic plasticity due to Ca2+-
dependent gene transcription.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
PC12 cellsbiological signal transductioncAMP response element binding proteincalcium fluxcalmodulin dependent protein kinasecell lineenzyme inhibitorsenzyme mechanismgene expressiongenetic regulatory elementgenetic transcriptionmitogen activated protein kinase
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
096997515
UEI
NPSNT86JKN51
Project Start Date
01-April-1999
Project End Date
31-March-2000
Budget Start Date
01-October-1998
Budget End Date
30-September-1999
Project Funding Information for 1999
Total Funding
$194,671
Direct Costs
Indirect Costs
Year
Funding IC
FY Total Cost by IC
1999
National Institute of Diabetes and Digestive and Kidney Diseases
$194,671
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01DK044239-08 0005
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01DK044239-08 0005
Patents
No Patents information available for 5P01DK044239-08 0005
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01DK044239-08 0005
Clinical Studies
No Clinical Studies information available for 5P01DK044239-08 0005
News and More
Related News Releases
No news release information available for 5P01DK044239-08 0005
History
No Historical information available for 5P01DK044239-08 0005
Similar Projects
No Similar Projects information available for 5P01DK044239-08 0005